Aflibercept Appears More Advantageous for Weaning Than Bevacizumab

Aflibercept (Eylea, Regeneron Pharmaceuticals) is better for weaning neovascular age-related macular degeneration patients off therapy than bevacizumab. In a retrospective analysis, aflibercept eyes were three times more likely to be weaned off treatment; vision was similar between treatments.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ